formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide avapro grapefruit preparations are marketed under similar trade names to irbesartan preparations, avapro grapefruit CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis.

(IUPAC) name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. avapro grapefruit 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic avapro grapefruit life 11–15 hoursExcretion avapro grapefruit 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonist avapro grapefruit mainly for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the treatment of hypertension. avapro grapefruit was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, including CoAprovel, avapro grapefruit Avalide and Avapro HCT.[edit] References^ Lewis EJ.

antagonist irbesartan in patients with nephropathy due to type 2 avapro grapefruit N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi.